X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12615) 12615
Book Review (3004) 3004
Publication (993) 993
Newspaper Article (122) 122
Newsletter (93) 93
Book Chapter (79) 79
Book / eBook (47) 47
Conference Proceeding (33) 33
Magazine Article (31) 31
Dissertation (6) 6
Trade Publication Article (6) 6
Streaming Video (5) 5
Web Resource (4) 4
Government Document (3) 3
Reference (3) 3
Paper (2) 2
Data Set (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (11124) 11124
index medicus (10613) 10613
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (6429) 6429
oncology (4836) 4836
hematology (4557) 4557
male (4131) 4131
imatinib mesylate (4130) 4130
chronic myelogenous leukemia (3997) 3997
female (3865) 3865
middle aged (3329) 3329
adult (3328) 3328
chronic myeloid leukemia (3239) 3239
leukemia (3103) 3103
benzamides (3086) 3086
antineoplastic agents - therapeutic use (3017) 3017
chronic myeloid-leukemia (2987) 2987
pyrimidines - therapeutic use (2696) 2696
leukemia, myelogenous, chronic, bcr-abl positive - genetics (2578) 2578
imatinib (2355) 2355
leukemia, myelogenous, chronic, bcr-abl positive - pathology (2323) 2323
piperazines - therapeutic use (2317) 2317
aged (2254) 2254
cancer (2236) 2236
animals (1854) 1854
bcr-abl (1834) 1834
protein kinase inhibitors - therapeutic use (1763) 1763
treatment outcome (1707) 1707
fusion proteins, bcr-abl - genetics (1554) 1554
hemic and lymphatic diseases (1378) 1378
antineoplastic agents - pharmacology (1377) 1377
research (1355) 1355
apoptosis (1309) 1309
care and treatment (1294) 1294
therapy (1264) 1264
cml (1256) 1256
leukemia, myelogenous, chronic, bcr-abl positive - therapy (1226) 1226
dasatinib (1225) 1225
adolescent (1186) 1186
pyrimidines - pharmacology (1172) 1172
mutation (1134) 1134
protein-tyrosine kinases - antagonists & inhibitors (1130) 1130
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (1101) 1101
acute lymphoblastic-leukemia (1047) 1047
mice (1032) 1032
drug resistance, neoplasm (1020) 1020
piperazines - pharmacology (996) 996
apoptosis - drug effects (965) 965
cell line, tumor (944) 944
antineoplastic agents - adverse effects (937) 937
genetic aspects (934) 934
abridged index medicus (906) 906
drug therapy (903) 903
tyrosine (897) 897
pyrimidines - adverse effects (889) 889
tyrosine kinase inhibitor (883) 883
protein kinase inhibitors - pharmacology (880) 880
prognosis (870) 870
analysis (854) 854
k562 cells (854) 854
pharmacology & pharmacy (853) 853
stem cells (839) 839
kinases (825) 825
philadelphia-chromosome (817) 817
pyrimidines - administration & dosage (816) 816
health aspects (813) 813
antineoplastic combined chemotherapy protocols - therapeutic use (811) 811
tyrosine kinase (798) 798
cell biology (796) 796
leukemia, myelogenous, chronic, bcr-abl positive - diagnosis (786) 786
tyrosine kinase inhibitors (783) 783
chemotherapy (775) 775
resistance (774) 774
medicine & public health (769) 769
fusion proteins, bcr-abl - metabolism (763) 763
antineoplastic agents (750) 750
aged, 80 and over (744) 744
hematology, oncology and palliative medicine (744) 744
transplantation (725) 725
young adult (721) 721
remission induction (703) 703
acute myeloid-leukemia (698) 698
philadelphia chromosome (698) 698
antineoplastic agents - administration & dosage (695) 695
chronic-phase (686) 686
fusion proteins, bcr-abl - antagonists & inhibitors (682) 682
proteins (682) 682
antimitotic agents (679) 679
nilotinib (679) 679
piperazines - administration & dosage (670) 670
drug resistance (652) 652
piperazines - adverse effects (643) 643
cells (640) 640
biochemistry & molecular biology (637) 637
interferon-alpha (608) 608
leukemia, myelogenous, chronic, bcr-abl positive - mortality (606) 606
drug resistance, neoplasm - genetics (603) 603
child (593) 593
in-vitro (588) 588
expression (580) 580
blast crisis (579) 579
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (34) 34
Collection Dvlpm't (Acquisitions) - Vendor file (6) 6
Online Resources - Online (6) 6
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Toronto East General Hospital - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12254) 12254
Japanese (218) 218
Chinese (146) 146
French (67) 67
German (59) 59
Spanish (56) 56
Russian (55) 55
Polish (30) 30
Hungarian (23) 23
Czech (15) 15
Danish (13) 13
Italian (10) 10
Portuguese (6) 6
Swedish (5) 5
Dutch (4) 4
Slovak (4) 4
Finnish (3) 3
Hebrew (3) 3
Norwegian (3) 3
Ukrainian (3) 3
Croatian (2) 2
Korean (2) 2
Romanian (2) 2
Serbian (1) 1
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer Cell, ISSN 1535-6108, 2009, Volume 16, Issue 5, pp. 401 - 412
Inhibition of BCR-ABL by imatinib induces durable responses in many patients with chronic myeloid leukemia (CML), but resistance attributable to kinase domain... 
CHEMBIO | HUMDISEASE | CHRONIC MYELOGENOUS LEUKEMIA | DASATINIB BMS-354825 | MESYLATE | CML | ONCOLOGY | KINASE DOMAIN MUTATIONS | AMN107 | IMATINIB RESISTANCE | NILOTINIB | Proto-Oncogene Proteins c-abl - antagonists & inhibitors | Humans | Imidazoles - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Crystallography, X-Ray | Pyridazines - pharmacology | Protein Kinase Inhibitors - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Antineoplastic Agents - pharmacology | Fusion Proteins, bcr-abl - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Proto-Oncogene Proteins c-abl - genetics | Cell Growth Processes - drug effects | Proto-Oncogene Proteins c-abl - chemistry | Models, Molecular | Imidazoles - pharmacology | Antineoplastic Agents - chemistry | Mice, SCID | Pyridazines - chemistry | Fusion Proteins, bcr-abl - genetics | Animals | Signal Transduction - drug effects | Fusion Proteins, bcr-abl - antagonists & inhibitors | Cell Line, Tumor | Proto-Oncogene Proteins c-abl - metabolism | Mice | Protein Kinase Inhibitors - pharmacology | Fusion Proteins, bcr-abl - metabolism | Chronic myeloid leukemia | BCR protein | Imatinib | Mutagenesis | Abl protein | Mutation | Fusion protein | Tumors | Index Medicus | imatinib resistance | dasatinib | nilotinib | compound mutation
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 01/2011, Volume 121, Issue 1, pp. 396 - 409
Journal Article
Journal Article
Cancer Cell, ISSN 1535-6108, 2008, Volume 14, Issue 3, pp. 238 - 249
Resistance of Bcr-Abl-positive leukemic stem cells (LSCs) to imatinib treatment in patients with chronic myeloid leukemia (CML) can cause relapse of disease... 
STEMCELL | CELLCYCLE | CHRONIC MYELOGENOUS LEUKEMIA | HEMATOPOIETIC-CELLS | MOLECULAR REMISSION | ONCOLOGY | SONIC HEDGEHOG | SIGNALING PATHWAY | PHILADELPHIA-CHROMOSOME | NEURAL-TUBE | IMATINIB MESYLATE DISCONTINUATION | MICE | CHRONIC MYELOID-LEUKEMIA | CELL BIOLOGY | Cell Proliferation | Fetal Stem Cells - cytology | Gene Expression - drug effects | Receptors, G-Protein-Coupled - metabolism | Apoptosis - drug effects | Neoplastic Stem Cells - drug effects | Fetal Stem Cells - metabolism | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Hedgehog Proteins - physiology | Hematopoiesis - drug effects | Neoplastic Stem Cells - metabolism | Kruppel-Like Transcription Factors - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology | Smoothened Receptor | Bone Marrow Transplantation | Veratrum Alkaloids - pharmacology | Neoplastic Stem Cells - pathology | Bone Marrow Cells - drug effects | Hematopoiesis - physiology | Patched Receptors | Drug Therapy, Combination | Veratrum Alkaloids - therapeutic use | Mice, Inbred C57BL | Bone Marrow Cells - pathology | Receptors, Cell Surface - metabolism | Mice, Transgenic | Pyrimidines - pharmacology | Mice, Knockout | Fusion Proteins, bcr-abl - genetics | Animals | Signal Transduction - drug effects | Pyrimidines - therapeutic use | Survival Analysis | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Signal Transduction - physiology | Fetal Stem Cells - transplantation | Mice | Receptors, G-Protein-Coupled - genetics | Zinc Finger Protein GLI1 | Kruppel-Like Transcription Factors - genetics | Bone Marrow Cells - metabolism | Fusion Proteins, bcr-abl - metabolism | Receptors, Cell Surface - genetics | Genetic research | Flexible response (Strategy) | Drug resistance | Deterrence (Strategy) | Leukemia | Stem cells | Index Medicus
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2009, Volume 27, Issue 25, pp. 4204 - 4210
Journal Article
Journal Article
Nature, ISSN 0028-0836, 01/2010, Volume 463, Issue 7280, pp. 501 - 506
In an effort to find new pharmacological modalities to overcome resistance to ATP-binding-site inhibitors of Bcr-Abl, we recently reported the discovery of... 
CELL LUNG-CANCER | KINASE-INHIBITOR | SELECTIVE INHIBITOR | C-ABL | TYROSINE KINASE | MULTIDISCIPLINARY SCIENCES | DYNAMICS | MUTATIONS | LYMPHOBLASTIC-LEUKEMIA | IMATINIB RESISTANCE | CHRONIC MYELOID-LEUKEMIA | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Male | Transplantation, Heterologous | Piperazines - chemistry | Pyrimidines - chemistry | Pyrimidines - metabolism | Antineoplastic Agents - metabolism | Mass Spectrometry | Bone Marrow Transplantation | Inhibitory Concentration 50 | Female | Antineoplastic Agents - pharmacology | Binding Sites | Disease Models, Animal | Fusion Proteins, bcr-abl - chemistry | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Protein Structure, Tertiary | Crystallization | Antineoplastic Combined Chemotherapy Protocols | Models, Molecular | Pyrimidines - pharmacology | Antineoplastic Agents - chemistry | Mutation - genetics | Imatinib Mesylate | Piperazines - pharmacology | Fusion Proteins, bcr-abl - genetics | Animals | Cell Line, Tumor | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Mice | Benzamides | Fusion Proteins, bcr-abl - metabolism | Drug Resistance, Neoplasm - drug effects | Nilotinib | Dasatinib | Drug resistance in microorganisms | Usage | Nuclear magnetic resonance spectroscopy | Research | Chronic myeloid leukemia | X-ray crystallography | Chromosome abnormalities | Gene mutations | Analysis | Genetic aspects | Diagnosis | Binding proteins | Drug therapy | Health aspects | Proteins | Studies | Competition | Enzymes | E coli | Kinases | Drug resistance | Crystal structure | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 03/2016, Volume 127, Issue 10, pp. 1269 - 1275
Journal Article
Nature Chemical Biology, ISSN 1552-4450, 03/2012, Volume 8, Issue 3, pp. 285 - 293
Journal Article